Biohaven Pharmaceutical Holding

General Information

We are a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Our product candidates are small molecules based on two distinct mechanistic platforms—calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators—which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.

Employees: 12
Founded: 2013
Contact Information
Address 234 Church Street, New Haven, CT 06510, US
Phone Number (203) 404-0410
Web Address
View Prospectus: Biohaven Pharmaceutical Holding
Financial Information
Market Cap $581.9mil
Revenues $0 mil (last 12 months)
Net Income $-63.7 mil (last 12 months)
IPO Profile
Symbol BHVN
Exchange NYSE
Shares (millions): 9.9
Price range $17.00 - $17.00
Est. $ Volume $168.3 mil
Manager / Joint Managers Morgan Stanley/ Piper Jaffray/ Barclays Capital
CO-Managers William Blair/ Needham & Company
Expected To Trade: 5/4/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change